PURPOSE: We used a superficial parotid lobe-sparing delineation approach for dose optimization with better protection for the parotid glands in intensity-modulated radiotherapy (imrt) for nasopharyngeal carcinoma (npc) patients. METHODS: Compared with traditional contouring of the entire parotid glands as organs at risk (oars) in imrt for npc, we used a superficial parotid lobe-sparing delineation approach of contouring the superficial parotid lobes as oars. Changes in dose to the parotid glands, the targets, and other oars were evaluated. RESULTS: The mean dose to the parotid glands overall decreased by more than 4 Gy in the test plans. Impressively, the mean dose to the superficial parotid lobes in the test plans was not more than 30 Gy, regardless of clinical stage. In T1-3 npc patients, the dose distributions for targets were not significantly different in the control plans and the test plans. However, for some T4 patients, the dose distributions for targets and brainstem in the test plans could not meet clinical requirements. CONCLUSIONS: The superficial parotid lobe-sparing delineation approach can significantly lower the mean dose to the entire parotid and to the superficial parotid lobe in T1-3 npc patients, which would be expected to result in less xerostomia and better quality of life for those patients.
PURPOSE: We used a superficial parotid lobe-sparing delineation approach for dose optimization with better protection for the parotid glands in intensity-modulated radiotherapy (imrt) for nasopharyngeal carcinoma (npc) patients. METHODS: Compared with traditional contouring of the entire parotid glands as organs at risk (oars) in imrt for npc, we used a superficial parotid lobe-sparing delineation approach of contouring the superficial parotid lobes as oars. Changes in dose to the parotid glands, the targets, and other oars were evaluated. RESULTS: The mean dose to the parotid glands overall decreased by more than 4 Gy in the test plans. Impressively, the mean dose to the superficial parotid lobes in the test plans was not more than 30 Gy, regardless of clinical stage. In T1-3 npc patients, the dose distributions for targets were not significantly different in the control plans and the test plans. However, for some T4 patients, the dose distributions for targets and brainstem in the test plans could not meet clinical requirements. CONCLUSIONS: The superficial parotid lobe-sparing delineation approach can significantly lower the mean dose to the entire parotid and to the superficial parotid lobe in T1-3 npc patients, which would be expected to result in less xerostomia and better quality of life for those patients.
Authors: Angel I Blanco; K S Clifford Chao; Issam El Naqa; Gregg E Franklin; Konstantin Zakarian; Milos Vicic; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-15 Impact factor: 7.038
Authors: E Shaw; R Kline; M Gillin; L Souhami; A Hirschfeld; R Dinapoli; L Martin Journal: Int J Radiat Oncol Biol Phys Date: 1993-12-01 Impact factor: 7.038
Authors: K Bjordal; M Ahlner-Elmqvist; E Hammerlid; M Boysen; J F Evensen; A Biörklund; M Jannert; T Westin; S Kaasa Journal: Laryngoscope Date: 2001-08 Impact factor: 3.325
Authors: Michael K M Kam; Sing-Fai Leung; Benny Zee; Ricky M C Chau; Joyce J S Suen; Frankie Mo; Maria Lai; Rosalie Ho; Kin-yin Cheung; Brian K H Yu; Samuel K W Chiu; Peter H K Choi; Peter M L Teo; Wing-hong Kwan; Anthony T C Chan Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544